Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $47,994 | $48,704 | $59,283 | $60,115 | $64,168 |
| Gross Profit | $32,509 | $35,078 | $41,872 | $43,989 | $48,975 |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Net Income | $7,067 | $13,049 | $14,519 | $365 | $17,117 |
Over the five-year period, Merck’s revenue showed a steady upward trend, increasing from approximately USD 48 billion in 2020 to roughly USD 64 billion in 2024. Gross profit followed suit, growing from around USD 32.5 billion to nearly USD 49 billion. Despite these positive trends, the operating income consistently remains reported as zero, which suggests that the available data may not capture the company's operating performance in detail or that there are specific accounting treatments at play in this dataset. Typically, one would expect operating income to mirror improvements in revenue and gross profit unless significant operating expenses, non-recurring items, or specific adjustments are being recorded elsewhere. Net income, however, demonstrated significant volatility over the period. After rising from USD 7.1 billion in 2020 to USD 14.5 billion in 2022, Merck experienced an unusual and pronounced drop to only USD 365 million in 2023, representing a drastic decline of over 97% year-over-year. This dramatic swing was then followed by a robust recovery to USD 17.1 billion in 2024—a jump that exceeds a 4700% increase from 2023. Such pronounced fluctuations in net income warrant further investigation as they may be driven by extraordinary items, tax adjustments, or one-off events not reflected in operating income. Overall, while the revenue and gross profit trends imply underlying business growth and market resilience, the erratic net income figures introduce questions regarding the sustainability of earnings profiles and call for deeper analysis into non-operating financial factors.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.